Camilla Sandberg
Amministratore Delegato presso MIRIS HOLDING AB
Posizioni attive di Camilla Sandberg
Società | Posizione | Inizio | Fine |
---|---|---|---|
MIRIS HOLDING AB | Amministratore Delegato | 04/10/2016 | - |
NEXTCELL PHARMA AB | Direttore/Membro del Consiglio | 01/01/2017 | - |
Independent Dir/Board Member | 01/01/2017 | - | |
MONIVENT AB | Direttore/Membro del Consiglio | - | - |
Independent Dir/Board Member | - | - |
Storia della carriera di Camilla Sandberg
Precedenti posizioni note di Camilla Sandberg
Società | Posizione | Inizio | Fine |
---|---|---|---|
BioLamina AB
BioLamina AB BiotechnologyHealth Technology BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden. | Vendite & Marketing | - | - |
Formazione di Camilla Sandberg
University of Oslo | Masters Business Admin |
Statistiche
Distribuzione geografica
Svezia | 5 |
Norvegia | 2 |
Posizioni
Director/Board Member | 2 |
Independent Dir/Board Member | 2 |
Chief Executive Officer | 1 |
Settori
Health Technology | 4 |
Electronic Technology | 2 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
MIRIS HOLDING AB | Electronic Technology |
NEXTCELL PHARMA AB | Health Technology |
MONIVENT AB | Health Technology |
Aziende private | 1 |
---|---|
BioLamina AB
BioLamina AB BiotechnologyHealth Technology BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden. | Health Technology |
- Borsa valori
- Insiders
- Camilla Sandberg
- Esperienza